Drug Database
Back to search

Poland· PL-100395662

Benlysta

A belimumab product containing belimumab, registered in Poland by GlaxoSmithKline (Ireland) Limited. The same ATC class is registered in 12 of our 19 countries.

ATC L04AG04

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedBenlystaATCL04AG04REGISTER NO.PL-100395662PACKS LISTED5CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about belimumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Belimumab is registered in 12 of 19 countries.

Countries holding a registration under ATC L04AG04 (belimumab), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search belimumab products by name

Belimumab · ATC L04AG04

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of belimumab costs, country by country.

Normalised to the WHO defined daily dose (25 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Belimumab · price per daily dose (25 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$45.43
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Belimumab
Manufacturer
GlaxoSmithKline (Ireland) Limited
Country
Poland (PL)
ATC code
L04AG04
ATC class
Belimumab
Defined daily dose
25 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 5

  • gtin
    05909991349820
  • gtin
    05909991349844
  • gtin
    05909991349813
  • gtin
    05909991349837
  • gtin
    05909991349806

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

61 interactions on record for belimumab.

Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check belimumab against other medicinesHow interaction checks work

Belimumab · interactions on record

61 records

  • 28 severe
  • 26 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Belimumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All belimumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Benlysta
  • Liechtenstein · Benlysta
  • Norway · Benlysta

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7a327e16-232e-4d0d-a819-f6c8caef4b34
GET /v1/drugs/7a327e16-232e-4d0d-a819-f6c8caef4b34?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "200 mg/ml",
  "packaging": "05909991349806 ¦ Rpz ¦ EU/1/11/700/003 ¦ 124975\n1 wstrzykiwacz 1 ml\n05909991349813 ¦ Rpz ¦ EU/1/11/700/006 ¦ 124976\n1 amp.-strzyk. 1 ml\n05909991349820 ¦ Rpz ¦ EU/1/11/700/007 ¦ 124977\n4 amp.-strzyk. 1 ml\n05909991349837 ¦ Rpz ¦ EU/1/11/700/004 ¦ 124978\n4 wstrzykiwacze 1 ml\n05909991349844 ¦ Rpz ¦ EU/1/11/700/005 ¦ 124979\n12 wstrzykiwaczy 1 ml",
  "substance": "Belimumabum 200 mg/ml",
  "common_name": "Belimumab",
  "pl_product_id": "100395662",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about belimumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console